HIPEC in ovarian cancer: Treatment of a new era or is it the end of the pipeline?

被引:10
作者
Cascales-Campos, P. [1 ]
Gil, J. [1 ]
Feliciangeli, E. [2 ]
Parrilla, P. [1 ]
机构
[1] Hosp Clin Univ Virgen de la Arrixaca, Unidad Cirugia Carcinomatosis Peritoneal, Serv Cirugia Gen & Aparato Digest, IMIB, Murcia, Spain
[2] Hosp Clin Univ Virgen de la Arrixaca, Serv Oncol Med, IMIB, Murcia, Spain
关键词
Ovarian cancer; Peritoneal surface malignancies; Cytoreduction; HIPEC; Postoperative intraperitoneal chemotherapy; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; STAGE-III OVARIAN; CYTOREDUCTIVE SURGERY; PERITONEAL CARCINOMATOSIS; PROGRESSION-FREE; INTRAVENOUS PACLITAXEL; FALLOPIAN-TUBE; FREE SURVIVAL; PHASE-I; CISPLATIN;
D O I
10.1016/j.ygyno.2015.06.012
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ovarian cancer is the leading cause of death from gynecological cancer in western countries. The absence of an effective screening program as well as specific symptoms, makes the diagnosis difficult and often made in advanced stages of the disease, in the presence of peritoneal dissemination. The complete cytoreduction of the disease and tumor sensitivity to systemic chemotherapy based on plafinums, are the two main prognostic factors. However in patients with complete cytoreduction the recurrence rate is high. The microscopic component of the disease at the end of the cytoreduction is responsible for these recurrences and the use of intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) in the same time of surgery has been proposed as a reasonable therapeutic option for treatment. However, the absence of sufficient levels of scientific evidence to support the use of HIPEC in patients with ovarian cancer with peritoneal dissemination does not allow a general recommendation outside of clinical trials. The main objective of this study is to identify the strengths and weaknesses of HIPEC treatment in ovarian cancer with peritoneal dissemination, and to know which points can be improved in the future. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:363 / 368
页数:6
相关论文
共 55 条
  • [1] Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer
    Alberts, DS
    Liu, PY
    Hannigan, EV
    OToole, R
    Williams, SD
    Young, JA
    Franklin, EW
    ClarkePearson, DL
    Malviya, VK
    DuBeshter, B
    Adelson, MD
    Hoskins, WJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (26) : 1950 - 1955
  • [2] The Role of Hyperthermic Intraperitoneal Chemotherapy Using Paclitaxel in Platinum-Sensitive Recurrent Epithelial Ovarian Cancer Patients with Microscopic Residual Disease after Cytoreduction
    Antonio Cascales-Campos, Pedro
    Gil, J.
    Feliciangeli, E.
    Gil, E.
    Gonzalez-Gil, A.
    Lopez, V.
    Ruiz-Pardo, J.
    Nieto, A.
    Parrilla, J. J.
    Parrilla, P.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (03) : 987 - 993
  • [3] Treatment of Microscopic Disease with Hyperthermic Intraoperative Intraperitoneal Chemotherapy After Complete Cytoreduction Improves Disease-Free Survival in Patients with Stage IIIC/IV Ovarian Cancer
    Antonio Cascales-Campos, Pedro
    Gil, J.
    Gil, E.
    Feliciangeli, E.
    Gonzalez-Gil, A.
    Parrilla, J. J.
    Parrilla, P.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (07) : 2383 - 2389
  • [4] Intraperitoneal cisplatin and paclitaxel in ovarian cancer
    Armstrong, DK
    Bundy, B
    Wenzel, L
    Huang, HQ
    Baergen, R
    Lele, S
    Copeland, LJ
    Walker, JL
    Burger, RA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) : 34 - 43
  • [5] Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery
    Bae, Jeong Hoon
    Lee, Joon Mo
    Ryu, Ki Sung
    Lee, Yong Seok
    Park, Yong Gyu
    Hur, Soo Young
    Ahn, Woong Shik
    Namkoong, Seong Eun
    [J]. GYNECOLOGIC ONCOLOGY, 2007, 106 (01) : 193 - 200
  • [6] Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Persistent and Recurrent Advanced Ovarian Carcinoma: A Multicenter, Prospective Study of 246 Patients
    Bakrin, N.
    Cotte, E.
    Golfier, F.
    Gilly, F. N.
    Freyer, G.
    Helm, W.
    Glehen, O.
    Bereder, J. M.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (13) : 4052 - 4058
  • [7] Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer
    Barlin, Joyce N.
    Dao, Fanny
    Zgheib, Nadim Bou
    Ferguson, Sarah E.
    Sabbatini, Paul J.
    Hensley, Martee L.
    Bell-McGuinn, Katherine M.
    Konner, Jason
    Tew, William P.
    Aghajanian, Carol
    Chi, Dennis S.
    [J]. GYNECOLOGIC ONCOLOGY, 2012, 125 (03) : 621 - 624
  • [8] Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer
    Bijelic, L.
    Jonson, A.
    Sugarbaker, P. H.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 (12) : 1943 - 1950
  • [9] The National Cancer Database report on advanced-stage epithelial ovarian cancer: Impact of hospital surgical case volume on overall survival and surgical treatment paradigm
    Bristow, Robert E.
    Palis, Bryan E.
    Chi, Dennis S.
    Cliby, William A.
    [J]. GYNECOLOGIC ONCOLOGY, 2010, 118 (03) : 262 - 267
  • [10] Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with primary and recurrent advanced ovarian cancer
    Cascales Campos, P.
    Gil, Jose
    Parrilla, Pascual
    [J]. EJSO, 2014, 40 (08): : 970 - 975